Novo Nordisk, a global healthcare company, completed the acquisition of Embark Biotech, a Danish biotech company, for €471m. "Novo Nordisk has been engaged in obesity research for 25 years, and we continuously search for new ways to address this serious chronic disease. We are excited about the opportunity to advance Embark Biotech's lead program and look forward to co-creating novel treatments for cardiometabolic diseases with Embark Laboratories to complement our in-house R&D," Brian Finan, Novo Nordisk Vice President of Obesity Research.